undamentalytics Newsletter
Sign in

Arvinas, Inc. (ARVN) stock

Add to watchlist

Add holding +

NASDAQ: ARVN Nasdaq Biotechnology Next results ~November 3, 2026

B+ Fundamentals grade

Arvinas, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$6.8

Valuation models combined (3)

Base case. Range ~$3.0–$9.3. Weighted average of 3 models (growth cash-flow model, forward price-to-sales vs peers, revenue-to-maturity model), the growth cash-flow model counting double.

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Arvinas, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 6 selling1 purchase and 23 sales by directors and officers, last 12 monthsInsider trades
  • Funds109 adding, 90 cuttingOf 46 active managers that changed their stake, 28 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Arvinas files

Where Arvinas stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $317m, down 15.0% on a year earlier, a smaller fall than the 79.1% decline a quarter earlier. That puts it 40 of 49 for growth among the biotechnology companies we cover. Free-cash-flow margin rose to -65.9% from -107.0% a year earlier. Operating margin widened to -5.7% from -31.8%. The diluted share count is down 7.6% on a year earlier, which lifts each remaining share. Against its peers on growth, profitability, cash generation and balance sheet, it grades B. It passes 6 of our 7 financial-health checks. Our revenue-to-maturity cash-flow model value is $7.28 a share, against a share price of $7.91.

Source: 10-Q filed August 4, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 3, 2026 (estimated)

Arvinas, Inc.'s trailing-twelve-month revenue fell 15.0% year on year, with a free-cash-flow margin of -65.9%. Where it stands out: change in share count of -7.6% ranks 2 of 156 biotechnology companies we cover.

Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 1012% in the quarter to 2026-06-30, the 3rd beat in the last four quarters.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Margins widening. Operating margin is up 26.1 points on a year ago.
  • Shrinking share count. Diluted shares fell 7.6% in a year, so each share owns more of the business.
  • Net cash. Cash exceeds long-term debt by $0.1bn.

Things to watch

  • Revenue shrinking. Revenue fell 15.0% over the last 12 months.
  • Loss-making. Operating margin is -5.7%: costs exceed revenue.
  • Burning cash. Free cash flow was -65.9% of revenue over the last 12 months.
  • High earnings multiple. The shares trade at 54 times the last 12 months' earnings, so expectations are demanding.
  • Volatile shares. Over the past year the shares showed annualised volatility of 55% and a beta of 1.2 against the S&P 500.
  • Weak cash conversion. Free cash flow was -2245% of net income over the last 12 months.

Latest results: FY2026 Q2

Filed August 4, 2026
Earnings per share
$2.58 against an average estimate of -$0.28: beat by 1012.4%
Revenue
$250m, up 1014.7% on a year earlier
Share reaction
+4.2% in the first session after the results on August 4, 2026, against +1.6% for the S&P 500
Next report
November 3, 2026; average EPS estimate -$0.95

Arvinas' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-4.3%
  • 1 week+2.9%
  • 1 month+1.5%
  • This year-36.6%
  • 1 year-25.8%
  • 5 years-91.9%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$317M
Operating margin
-5.7%
Net margin
2.9%
EPS (TTM, diluted)
$0.14

Growth

Revenue growth
−15.0%
Change in growth rate
+64.0 pts
Share count change
−7.6%

Cash

Free cash flow (TTM)
-$209M
FCF margin
-65.9%
Stock pay % of revenue
11.6%

Earnings

Last results
November 3, 2026
Next results (est.)
February 23, 2027

News & updates

Updated November 3, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Arvinas, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value Arvinas, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.6%: the 10-year Treasury yield (4.9%) plus a beta of 1.04 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$9.3 ~$8.8–$9.7 Primary model, counts double
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. ~$1.3 ~$1.0–$3.0 Left out: out of range vs price (0.17x)
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$3.0 ~$3.1–$12 Included, half weight
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$3.7 ~$3.7–$4.0 Included
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$6.8 ~$3.0–$9.3 3 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Arvinas, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20182019202020212022202320242025Now
Share price$12.85$41.09$84.93$82.14$34.21$41.16$19.17$11.86$7.52
Market value$121m$1.4bn$3.4bn$4.1bn$1.8bn$2.3bn$1.4bn$841m$503m
+ Net debt (− = net cash)−$1m−$7m−$586m−$107m−$80m−$311m−$100m−$142m−$94m
Enterprise value$120m$1.3bn$2.8bn$4.0bn$1.7bn$2.0bn$1.3bn$699m$409m
Multiples
Price / sales 8.5x31.4x129.5x76.6x13.9x29.1x5.2x3.2x1.6x
Price / earnings ————————54.1x
Price / free cash flow ———7.4x—————
EV / EBITDA —————————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

9 /100

Weak moat

How hard Arvinas's competitive advantage looks for rivals to wear away, judged from 9 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -25.3% of total assets over 8 years.

  • Durability 10 / 20

    Operating margin has been a median -208.7%; its worst year was -660.3%.

  • Cash conversion 1 / 20

    Free cash flow was positive in 1 of 8 years, at a median -164.8% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 50.2% over five years; stock-based pay has been a median 58.5% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (14 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 3, 2026, before the open. Analysts expect revenue of $17m and EPS of −$0.95 (range −$1.20 to −$0.28) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.14 +88% $296m +13%
Next −$3.23 −2259% $64m −78%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −95.2% on 90 days ago. In the last 30 days, 10 analysts raised Arvinas, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Arvinas, Inc., last 90 days
−$4.00 −$3.00 −$2.00 −$1.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$2.86 Current fiscal year, 60 days ago: −$0.11 Current fiscal year, 30 days ago: −$0.10 Current fiscal year, 7 days ago: −$0.14 Current fiscal year, Now: −$0.14 −$0.14 Next fiscal year, 90 days ago: −$3.45 Next fiscal year, 60 days ago: −$3.11 Next fiscal year, 30 days ago: −$3.08 Next fiscal year, 7 days ago: −$3.23 Next fiscal year, Now: −$3.23 −$3.23

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$2.86−$3.45
60 days ago −$0.11−$3.11
30 days ago −$0.10−$3.08
7 days ago −$0.14−$3.23
Now −$0.14−$3.23

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.28 $2.58 +1012.4%
Mar 2026 −$0.96 −$0.90 +6.7%
Dec 2025 −$0.57 −$1.10 −94.3%
Sept 2025 −$0.74 −$0.48 +35.5%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 4, 2026

No numeric guidance in Arvinas, Inc.'s latest earnings release (filed August 4, 2026). Some companies give their outlook only on the earnings call.

Analyst recommendations

16 analysts, Oct 2026
Buy744%
Hold850%
Sell16%

Monthly trend

  1. Oct 202625816
  2. Sep 202625816
  3. Aug 202625816
  4. Jul 202626716

Counts of recommendations published by analysts covering Arvinas, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
10.0%
of tradable shares
Days to cover
6.68
at average volume
Short interest, 1 month
+12%
to October 15, 2026
Held by institutions
84%
of shares
Held by insiders
7.8%
of shares
Employees
246
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −25.8%

$10.14 on October 31, 2025 to $7.52

ThenNowEffect
Revenue (last 12 months) $373m $317m −15.0%
P/S multiple 2.0x 1.6x −19.4%
Share count 72m 67m +8.3%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years −57.1%

$17.52 on November 3, 2023 to $7.52

ThenNowEffect
Revenue (last 12 months) $158m $317m +100.4%
P/S multiple 5.9x 1.6x −73.1%
Share count 53m 67m −20.3%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
ARVN−3%−58%+20%−53%−38%−37%
Industry peers (median)−36%−56%−18%−28%−5%−26%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
ARVN58%42%33%50%67%27%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
ARVN−39%−61%−62%−66%−70%−51%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since September 27, 2018: 94% from July 29, 2021 to May 14, 2025. Getting back needed a 1677% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$6.82 – $13.83
From 52-week high
−45.6%
vs 50-day average
−6.8%
vs 200-day average
−22.2%
Volatility (1 year)
55%
Beta vs S&P 500
1.17

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
5 up, 6 down
typical move ±6.7%
After a week
4 up, 7 down
typical move ±8.8%
After a month
3 up, 8 down
typical move ±19.3%
Results releasedNext dayS&P 500 next day5 days21 days
August 4, 2026 +4.2% +1.6% +11.5% +19.0%
May 12, 2026 +2.2% +0.4% −11.5% −26.6%
February 24, 2026 +8.1% +1.6% +8.6% −11.2%
November 5, 2025 +4.8% −0.7% +9.1% +34.1%
August 6, 2025 −18.0% +0.7% −6.8% +2.9%
May 1, 2025 −19.8% +2.2% −29.2% −23.8%
February 11, 2025 −5.4% −0.2% −2.3% −54.9%
October 30, 2024 −3.9% −2.3% +1.8% −2.8%
July 30, 2024 −1.0% +1.1% −9.4% −7.2%
May 7, 2024 +0.3% +0.1% −2.8% −14.1%
February 27, 2024 −5.8% +0.1% −4.3% −15.3%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Arvinas, Inc. in five measures

Fundamentals grade B+
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Arvinas, Inc.
$0 $200M $400M $600M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $159.4M Revenue (TTM), FY23 Q4: $78.5M Revenue (TTM), FY24 Q1: $71.3M Revenue (TTM), FY24 Q2: $93.3M Revenue (TTM), FY24 Q3: $161.1M Revenue (TTM), FY24 Q4: $263.4M Revenue (TTM), FY25 Q1: $426.9M Revenue (TTM), FY25 Q2: $372.8M Revenue (TTM), FY25 Q3: $312.3M Revenue (TTM), FY25 Q4: $262.6M Revenue (TTM), FY26 Q1: $89.4M Revenue (TTM), FY26 Q2: $316.7M $316.7M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $159.4M
FY23 Q4 $78.5M
FY24 Q1 $71.3M
FY24 Q2 $93.3M
FY24 Q3 $161.1M
FY24 Q4 $263.4M
FY25 Q1 $426.9M
FY25 Q2 $372.8M
FY25 Q3 $312.3M
FY25 Q4 $262.6M
FY26 Q1 $89.4M
FY26 Q2 $316.7M
Revenue growth, TTM YoY Arvinas, Inc.
-200% 0% 200% 400% 600% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 25.8% Revenue growth, TTM YoY, FY23 Q4: -40.2% Revenue growth, TTM YoY, FY24 Q1: -48.1% Revenue growth, TTM YoY, FY24 Q2: -40.9% Revenue growth, TTM YoY, FY24 Q3: 1.1% Revenue growth, TTM YoY, FY24 Q4: 235.5% Revenue growth, TTM YoY, FY25 Q1: 498.7% Revenue growth, TTM YoY, FY25 Q2: 299.6% Revenue growth, TTM YoY, FY25 Q3: 93.9% Revenue growth, TTM YoY, FY25 Q4: -0.3% Revenue growth, TTM YoY, FY26 Q1: -79.1% Revenue growth, TTM YoY, FY26 Q2: -15.0% -15.0%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 25.8%
FY23 Q4 -40.2%
FY24 Q1 -48.1%
FY24 Q2 -40.9%
FY24 Q3 1.1%
FY24 Q4 235.5%
FY25 Q1 498.7%
FY25 Q2 299.6%
FY25 Q3 93.9%
FY25 Q4 -0.3%
FY26 Q1 -79.1%
FY26 Q2 -15.0%
Operating margin (TTM) Arvinas, Inc.
-600% -400% -200% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -195.6% Operating margin (TTM), FY23 Q4: -511.5% Operating margin (TTM), FY24 Q1: -556.9% Operating margin (TTM), FY24 Q2: -397.6% Operating margin (TTM), FY24 Q3: -221.8% Operating margin (TTM), FY24 Q4: -95.0% Operating margin (TTM), FY25 Q1: -22.4% Operating margin (TTM), FY25 Q2: -31.8% Operating margin (TTM), FY25 Q3: -32.7% Operating margin (TTM), FY25 Q4: -45.1% Operating margin (TTM), FY26 Q1: -283.8% Operating margin (TTM), FY26 Q2: -5.7% -5.7%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -195.6%
FY23 Q4 -511.5%
FY24 Q1 -556.9%
FY24 Q2 -397.6%
FY24 Q3 -221.8%
FY24 Q4 -95.0%
FY25 Q1 -22.4%
FY25 Q2 -31.8%
FY25 Q3 -32.7%
FY25 Q4 -45.1%
FY26 Q1 -283.8%
FY26 Q2 -5.7%
FCF margin (TTM) Arvinas, Inc.
-600% -400% -200% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -213.2% FCF margin (TTM), FY23 Q4: -446.8% FCF margin (TTM), FY24 Q1: -499.3% FCF margin (TTM), FY24 Q2: -232.7% FCF margin (TTM), FY24 Q3: -161.3% FCF margin (TTM), FY24 Q4: -99.1% FCF margin (TTM), FY25 Q1: -59.2% FCF margin (TTM), FY25 Q2: -107.0% FCF margin (TTM), FY25 Q3: -105.5% FCF margin (TTM), FY25 Q4: -105.0% FCF margin (TTM), FY26 Q1: -287.4% FCF margin (TTM), FY26 Q2: -65.9% -65.9%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -213.2%
FY23 Q4 -446.8%
FY24 Q1 -499.3%
FY24 Q2 -232.7%
FY24 Q3 -161.3%
FY24 Q4 -99.1%
FY25 Q1 -59.2%
FY25 Q2 -107.0%
FY25 Q3 -105.5%
FY25 Q4 -105.0%
FY26 Q1 -287.4%
FY26 Q2 -65.9%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 8 14 43 26 54 131 79 263 263 317
EBITDA −24 −43 −50 −118 −184 −257 −397 −246 −116 −15
Operating income −25 −44 −52 −121 −188 −263 −402 −250 −119 −18
Net income −24 −41 −70 −119 −191 −283 −367 −199 −81 9
Diluted EPS −$3.02 −$25.45 −$2.13 −$3.02 −$3.82 −$5.31 −$6.62 −$2.77 −$1.14 $0.14
Growth (year on year)
Revenue — +89.0% +200.2% −39.8% +106.9% +145.1% −40.3% +235.5% −0.3% −15.0%
Margins
EBITDA margin −322.1% −300.9% −116.0% −454.1% −342.5% −195.5% −505.4% −93.2% −44.0% −4.8%
Operating margin −326.7% −305.8% −119.8% −466.4% −351.5% −200.3% −511.5% −95.0% −45.1% −5.7%
Net margin −317.3% −289.6% −163.5% −460.6% −356.3% −215.0% −467.9% −75.5% −30.8% 2.9%
Free-cash-flow margin 54.1% −132.3% −109.1% −371.0% >999% −213.3% −446.8% −99.1% −105.0% −65.9%
Cash flow
Cash from operations 5 −16 −41 −90 559 −274 −348 −259 −274 −207
Capital spending 1 3 6 6 5 7 3 2 2 2
Free cash flow 4 −19 −47 −96 555 −280 −351 −261 −276 −209
Stock-based pay 0 12 20 30 57 76 72 88 44 37
Free cash flow after stock pay 4 −31 −67 −126 498 −356 −422 −349 −320 −245
Balance sheet
Cash 31 3 9 588 108 81 312 101 143 94
Total debt 0 2 2 2 1 1 1 1 1 1
Net debt (negative = net cash) −31 −1 −7 −586 −107 −80 −311 −100 −142 −94
Diluted shares 9m 9m 33m 40m 50m 53m 56m 72m 71m 67m
Returned to shareholders
Buybacks — — — — — — 0 0 92 —
Total returned — — — — — — 0 0 92 —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

6 of 7 checks passed · June 30, 2026
What it owns · $675m
Short-term assets $652mLonger-term assets $23m
What it owes, and who funded it · $675m
Short-term liabilities $83mLonger-term liabilities $30mShareholders' equity $562m
  • Short-term assets cover short-term liabilities $652m of assets due within a year against $82m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $652m short-term assets against $30m of longer-dated liabilities.
  • More cash than debt $94m of cash against $500,000 of debt.
  • Debt below 40% of shareholders' equity Debt is 0% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 0% to 0% over five years.
  • A year's operating cash flow covers at least 20% of debt −$207m of operating cash flow against $500,000 of debt.
  • Operating profit covers interest at least five times over No material interest expense reported.

From Arvinas, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Buybacks, last 3 fiscal years
$91.9M
Diluted share count
−7.6%
year over year
R&D spending
75.4%
of revenue
Days sales outstanding
58 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated ARVN IOVA ADPT VCEL VIR SNDX Median
Revenue, last 12 months $317m $325m $308m $306m $303m $290m $56m
Revenue growth, last 12 months −15.0% 34.5% 50.1% 23.0% >999% 159.7% 12.6%
Revenue growth, 3-year average 26.1% — 17.6% 19.8% −14.8% 177.8% 13.7%
Revenue growth, latest quarter >999% 65.7% 21.5% 22.5% >999% 81.6% 10.2%
Gross margin — 48.4% 75.6% 74.6% 96.1% — 82.9%
Operating margin −5.7% −92.7% −12.2% 6.0% −92.4% −61.7% −189.4%
Operating margin, 3-year average −145.1% −554.7% −66.8% 1.6% <−999% −781.5% −363.5%
Net margin 2.9% −89.1% −20.7% 7.9% −83.0% −72.3% −169.8%
Cash from operations / revenue −65.4% −81.3% −6.8% 22.7% −66.8% −61.2% −168.0%
Free-cash-flow margin −65.9% −91.2% −7.8% 20.1% −67.1% −61.2% −162.4%
Free-cash-flow margin, 3-year average −135.2% −482.4% −43.0% 5.3% <−999% −652.6% −310.0%
Stock pay / revenue 11.6% 14.4% 15.9% 12.2% 15.5% 18.2% 20.0%
Change in share count −7.6% 29.6% 4.1% 0.6% 8.2% 2.5% 8.2%

Median of all 184 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth -15.0% 12.6% 122 of 172
Change in growth rate Growth +64.0pp -0.1pp 24 of 172
Operating margin Profitability -5.7% -189.4% 40 of 175
Net margin Profitability 2.9% -157.3% 36 of 180
Free-cash-flow margin Cash generation -65.9% -145.4% 71 of 176
Stock pay as % of revenue Cash generation 11.6% 19.2% 66 of 179
Long-term debt as % of assets Balance sheet 0.0% 20.6% 11 of 78
Change in share count Balance sheet -7.6% 7.9% 2 of 156
Days sales outstanding Balance sheet 58 days 75 days 38 of 100

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$474M
Institutions reporting
198
Shares held vs prior quarter
▲ 3.8%
Positions opened / closed
31 / 37

Top buyers and sellers, Q2 2026: 109 institutions bought and 90 sold ; the biggest buyer was Armistice Capital, LLC (+818K shares) and the biggest seller Tcg Crossover Management, LLC (−1.7M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $63.2M 7.6M 13.3% ▲ 11.9%
Vanguard Portfolio Management LLC $34.3M 4.1M 7.2% ▲ 6.0%
D. E. Shaw & Co., Inc. $29M 3.5M 6.1% ▼ 3.9%
Pfizer Inc $27.7M 3.5M 5.8% 0.0%
Armistice Capital, LLC $23.2M 2.8M 4.9% ▲ 41.4%
Vanguard Capital Management LLC $22.6M 2.7M 4.8% ▲ 0.9%
Two Sigma Investments, LP $21.4M 2.6M 4.5% ▲ 40.5%
State Street Corp $18.3M 2.2M 3.8% ▲ 20.1%
Nextech Invest Ltd. $17.1M 1.1M 3.6% ▲ 108.1%
Geode Capital Management, LLC $13.9M 1.7M 2.9% ▲ 7.1%
Qube Research & Technologies Ltd $13.2M 1.6M 2.8% ▲ 32.5%
Jacobs Levy Equity Management, Inc $11.7M 1.4M 2.5% ▼ 2.0%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Arvinas, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $268,000 1 trade by 1 insider, last 12 months Insider sales History → $1.4M 23 trades by 6 insiders · 5% under pre-set plans
Net ▼ $1.2M net selling
Insider Date Trade Shares Price Value
Saik Andrew Chief Financial Officer June 24, 2026 Sell pre-set plan 5,696 $8.16 $46,479
Cacace Angela M Chief Scientific Officer June 17, 2026 Sell pre-set plan 2,576 $7.60 $19,578
Teel Randy President and CEO May 21, 2026 Sell 2,209 $9.04 $19,969
Teel Randy President and CEO May 11, 2026 Sell 9,657 $9.94 $95,991
Berkowitz Noah Chief Medical Officer May 11, 2026 Sell 11,108 $9.94 $110,414
Cacace Angela M Chief Scientific Officer May 11, 2026 Sell 9,657 $9.94 $95,991
Loomis David K VP, Chief Accounting Officer May 11, 2026 Sell 1,919 $9.94 $19,075
Saik Andrew Chief Financial Officer May 11, 2026 Sell 11,139 $9.94 $110,722
Berkowitz Noah Chief Medical Officer March 18, 2026 Sell 6,435 $11.10 $71,428
Morrison Briggs Director March 6, 2026 Buy 20,000 $13.40 $268,000
Houston John G Director February 27, 2026 Sell 11,787 $13.14 $154,881
Houston John G Director February 27, 2026 Sell 18,822 $13.24 $249,203

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around February 23, 2027 estimated from the company's past filing pattern, not announced

  • November 3, 2026
  • August 4, 2026
  • May 12, 2026
  • February 24, 2026
  • November 5, 2025
  • August 6, 2025

Recent SEC filings

Data status

When each part of this page on Arvinas, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Arvinas, Inc. in brief

What does Arvinas, Inc. do?
Arvinas, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Arvinas, Inc.'s stock ticker?
Arvinas, Inc. trades under the ticker ARVN on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Arvinas, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Arvinas, Inc. reported revenue of $317M, 15.0% lower than a year earlier, according to its SEC filings.
What is Arvinas, Inc.'s free cash flow?
Arvinas, Inc.'s free-cash-flow margin is -65.9% of revenue over the trailing twelve months, ranking 71 of the 176 biotechnology companies we cover.
Who are Arvinas, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Vanguard Portfolio Management LLC and D. E. Shaw & Co., Inc. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Arvinas, Inc.'s market cap?
On November 2, 2026, Arvinas, Inc.'s market capitalisation was about $503M, with a price-to-earnings ratio of 54.1 and net debt of -$93.8M. Market figures come from third-party market data and may be delayed.
How much debt does Arvinas, Inc. have?
Arvinas, Inc.'s debt-to-equity ratio is 0.1%, from its latest balance sheet (0.1% five years earlier). The financial health section below sets out its other solvency checks.
Who are Arvinas, Inc.'s competitors?
In our Biotechnology peer group, the companies closest to Arvinas, Inc. are Iovance Biotherapeutics, Inc., Adaptive Biotechnologies Corp, Vericel Corp, Vir Biotechnology, Inc. and Syndax Pharmaceuticals Inc. The side-by-side comparison below sets their revenue, margins and growth against Arvinas, Inc.'s.
Are insiders buying or selling Arvinas, Inc. stock?
Over the last 12 months, Arvinas, Inc.'s directors and officers reported 1 open-market purchases and 23 sales on Form 4. The insider trading page charts every trade.
When is Arvinas, Inc.'s next earnings date?
Around November 3, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Arvinas, Inc. announces its own schedule.